DITHIOCARBAMATE PESTICIDE EXPOSURES, ALDEHYDE DEHYDROGENASE INHIBITION, AND RISK OF PARKINSON’S DISEASE

2011 ◽  
Vol 2011 (1) ◽  
Author(s):  
Beate Ritz ◽  
Shannon L. Rhodes ◽  
Arthur G. Fitzmaurice ◽  
Myles Cockburn ◽  
Jeff M. Bronstein
2014 ◽  
Vol 20 ◽  
pp. S68-S72 ◽  
Author(s):  
Tanja Maria Michel ◽  
Ludwig Käsbauer ◽  
Wieland Gsell ◽  
Julia Jecel ◽  
Abigail Jane Sheldrick ◽  
...  

2005 ◽  
Vol 73 (3) ◽  
pp. 136-139 ◽  
Author(s):  
Deborah A. Cory-Slechta ◽  
Mona Thiruchelvam ◽  
Eric K. Richfield ◽  
Brian K. Barlow ◽  
Andrew I. Brooks

Author(s):  
Tamilanban T ◽  
Manasa K ◽  
Chitra V

Background: Parkinson’s disease (PD) exhibits the extra pyramidal symptoms caused due to the dopaminergic neuronal degeneration in the substantia nigra of the brain and depletion of aldehyde dehydrogenase (ALDH) enzyme. Objective: This study was designed to enlighten the importance of Aldehyde dehydrogenase enzyme in protecting the dopamine levels in a living system. Camalexin, a potentially active compound has been evaluated for its dopamine enhancing and aldehyde dehydrogenase protecting role in pesticide induced Parkinson’s disease. Methods: AutoDock 4.2 software was employed to perform the docking simulations between the ligand camalexin and standard drugs Alda-1, Ropirinole with three proteins 4WJR, 3INL, 5AER. Consequently, the compound was evaluated for its in vivo neuroprotective role in zebrafish model by attaining Institutional Animal Ethical Committee permission. The behavioral assessments and catecholamine analysis in zebrafish were performed. Results: The Autodock result shows that the ligand camalexin has a lower binding energy (-3.84) that indicate higher affinity with the proteins when compared to the standard drug of proteins (-3.42). In zebrafish model, behavioral studies provided an evidence that camalexin helps in improvement of motor functions and cognition. The catecholamine assay has proved there is an enhancement in dopamine levels, as well as an improvement in aldehyde dehydrogenase enzyme also. Conclusion: The novel compound, camalexin, hence offers a protective role in Parkinson’s disease model by its interaction with neurochemical proteins and also in alternative in vivo model.


2015 ◽  
Vol 123 (11) ◽  
pp. 1123-1129 ◽  
Author(s):  
Frédéric Moisan ◽  
Johan Spinosi ◽  
Laurène Delabre ◽  
Véronique Gourlet ◽  
Jean-Louis Mazurie ◽  
...  

2015 ◽  
Vol 133 (1) ◽  
pp. 14-25 ◽  
Author(s):  
David S. Goldstein ◽  
Patti Sullivan ◽  
Adele Cooney ◽  
Yunden Jinsmaa ◽  
Irwin J. Kopin ◽  
...  

2014 ◽  
Vol 27 (8) ◽  
pp. 1359-1361 ◽  
Author(s):  
John E. Casida ◽  
Breanna Ford ◽  
Yunden Jinsmaa ◽  
Patti Sullivan ◽  
Adele Cooney ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document